Exercise protein cardiotrophin 1 (CT1) stimulates the growth of blood vessels, helps the growth of heart muscle & ventricle in a healthy way and improves the ability of the heart to pump more blood
Scientists of the study say about 50 percent of heart failure cases are due to the weakness in the right-sided or right ventricle (RV) of the heart. There are limited effective pharmacologic intervention or therapy options for patients with complications related to right-sided or right ventricle (RV) heart failure.
Even though there are drugs to treat left ventricle heart failure, but the treatments cannot fix the problem. Over a period of time, right ventricle (RV) of the heart to fail due to the failure of the left ventricle. The growth of the remaining heart muscles after heart failure will be dysfunctional and this growth may not help the heart in pumping more blood. The only treatment option left for advanced right-sided or right ventricle (RV) heart failure is a heart transplant.
Studies show that exercise enables growth of heart muscles, increases the elasticity of the heart muscles and enables the heart to pump more blood efficiently. But heart failure patients may not be well enough to do the exercise.
A study done by researchers at the Ottawa Hospital Research Institute, the University of Ottawa Canada and Carleton University, Ottawa shows a treatment option for people with right-sided or right ventricle (RV) heart failure condition with an "exercise" protein known as cardiotrophin-1 (CT1). Cardiotrophin-1 (CT1) protein will be produced in the body during "exercise" or during pregnancy.
The CT1 protein helps in uniform growth of the heart muscle and also stimulates the growth of blood vessels in the heart resulting in an increase in the ability of the heart in pumping more blood as if the heart patient is doing exercise or in the state of pregnancy. So with this mimicking, heart pumps more blood and grow in a healthy way.
Cardiotrophin 1 (CT1) protein trials with mice & rat models and with the cells growing in the lab show improvement in the repair of the damaged part of the heart (and heart muscle), improvement in the blood flow and improvement in the ability of the heart to pump more blood. The growth of the heart muscle with cardiotrophin-1 (CT1) protein is comparable to the growth of heart muscle associated with exercise. They also noticed heart growing to normal size with the stimulation of cardiotrophin-1 protein.
Researchers say their findings are very promising for the treatment of right-sided or right ventricle (RV) heart failure. Need for the heart transplant may not arise once this treatment procedure was implemented. Professor Duncan Stewart, a cardiologist and co-senior author of the study says the current experimental therapy can able treat both left and right ventricle (RV) heart failure. Researchers are planning for clinical trials within three to four years.
Senior author of the study was Dr. Lynn Megeney, at the Ottawa Hospital Research Institute. Co-author of the study was Dr. Patrick Burgon. The study findings were published on August 8, 2017, in the journal Cell Research. Title of the article was "Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.